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Abstract
Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson’s disease (PD) therapy.
Leucine-rich repeat kinase 2 (LRRK2) mutations account for up to 13 % of familial cases of PD. LRRK2 N-terminal
domain encompasses several serine residues that undergo phosphorylation influencing LRRK2 function. This work
aims at investigating whether LRRK2 phosphorylation/function may be involved in the molecular pathways
downstream D1 dopamine receptor leading to LIDs. Here we show that LRRK2 phosphorylation level at serine 935
correlates with LIDs induction and that inhibition of LRRK2 induces a significant increase in the dyskinetic score in
L-DOPA treated parkinsonian animals. Our findings support a close link between LRKK2 functional state and L-
DOPA-induced abnormal motor behaviour and highlight that LRRK2 phosphorylation level may be implicated in
LIDs, calling for novel therapeutic strategies.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the progressive loss of dopaminergic
neurons from the substantia nigra pars compacta, result-
ing in a decrease of dopamine (DA) levels in the striatum.
Up-to-date, DA replacement with L-3,4-dihydroxypheny-
lalanine methyl ester hydrochloride (L-DOPA) is the most
effective therapeutic approach for PD. Unfortunately, as
the disease progresses, L-DOPA administration is respon-
sible for severe side effects known as L-DOPA-induced
dyskinesias (LIDs) [1]. The most parsimonious explan-
ation of LIDs involves overactivation of D1 dopamine re-
ceptor (D1R) and extracellular signal regulated kinases 1
and 2 (ERK1/2) [1–3].
Leucine-rich repeat kinase 2 (LRRK2) mutations ac-
count for up to 13 % of familial PD cases compatible
with dominant inheritance [4, 5] and have been iden-
tified in 1–2 % of sporadic PD patients [6]. LRRK2 is
a large protein encompassing several functional do-
mains including a kinase domain similar to mitogen
activated protein kinase kinase kinases (MAPKKK)
and N- and C-terminal protein interaction domains
[7, 8]. LRRK2 is phosphorylated in vitro by a variety
of serine/threonine kinases, including protein kinase C
(PKC) zeta, serine protein kinase ataxia telangiectasia mu-
tated, the IκB kinase family, and cyclic adenosine monopho-
sphate-dependent protein kinase (PKA) [9]. Accumulating
evidence suggest that Ser 910 and 935 within LRRK2 N-
terminal domain undergo dynamic activity-dependent
phosphorylation/dephosphorylation cycle. In particular,
LRRK2 is phosphorylated on Ser-935/910 by PKA
[10], and, at the same time, it regulates PKA signalling
to the ERK1/2 pathway [11]. Notably, it has also been
suggested that LRRK2 influences synaptogenesis and
D1R and GluR1 signalling via PKA [11]. In this study
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we hypothesize that LRRK2 may be involved in the
molecular pathway downstream D1R activation lead-
ing to LIDs.
Results
Given the tight functional correlation between LRRK2 and
crucial LIDs molecular players, we measured LRRK2 ex-
pression and phosphorylation levels in the striatum from
control, 6-OHDA and L-DOPA-treated non dyskinetic
and dyskinetic rats. Interestingly, while LRRK2 total ex-
pression was unaltered in the different experimental
groups, LRRK2 phosphorylation at Ser-935 (P-935;
Fig. 1a-b) was significantly modified following treatment
with L-DOPA. In particular, dyskinetic animals were char-
acterized by a significant decrease in P-935 tone compared
to non dyskinetic rats. Conversely, non dyskinetic rats
were characterized by a significantly higher P-935 level
compared to 6-OHDA animals (Fig. 1a-b).
Based on the above-described molecular results, we
questioned whether LRRK2 phosphorylation level could
directly correlate with LIDs onset. To prove this hypoth-
esis, we first evaluated the efficacy of LRRK2 inhibitors
in vivo. To this, we injected in the left striatum of naive
rats 5 nmol of IN-1 inhibitor [12] or its vehicle (0.5 %
DMSO). The treatment with either DMSO or IN-1 did
not influence the motor behaviour of naive animals (data
not shown). After 2 h, we sacrificed the animals and re-
moved the ipsi and controlateral striata. Next, we proc-
essed striatal specimen for biochemical investigation.
Indeed, IN-1 reduced LRRK2 phosphorylation at Ser-935
in vivo (Fig. 1c-d). LRRK2 inhibitor III was already de-
scribed as capable to pass the blood brain barrier (BBB)
and inhibit LRRK2 in the central nervous system [13].
Considering that LRRK2 phosphorylation level in-
versely correlates with LIDs (Fig. 1a-b), we verified if ad-
ministration of IN-1 and LRRK2 inhibitor III to rats
without a dyskinetic profile could affect their motor be-
haviour. Therefore, IN-1 (5 nmol), LRRK2 inhibitor III
(5 nmol) or vehicle (5 μl 0.5 % DMSO) were injected in
the ipsilateral striatum of 6-OHDA-lesioned rats display-
ing a low dyskinetic behaviour following L-DOPA
chronic treatment (15 days; Fig. 2a). Intrastriatal injec-
tions were performed 6 h before the daily injection of L-
DOPA. As shown in Fig. 2b, both inhibitors were able to
induce a significant and similar increase in the total
AIMs score compared to vehicle injected rats and pre-
surgery scores. Moreover, the time course of AIMs de-
velopment (Fig. 2c-e) indicated a more pronounced ef-
fect of LRRK2 inhibitor III compared to IN-1 in AIMs
induction, as measured during the single last observation
Fig. 1 LRRK2 phosphorylation at Ser-935 in parkinsonian and dyskinetic rats. a The ipsilateral striatum from non lesioned (control), fully lesioned
parkinsonian (6-OHDA), non dyskinetic (Non Dys) rats or animals displaying a dyskinetic behaviour (Dys) were analyzed by WB to evaluate the
levels of LRRK2 phosphorylation at Ser-935 site (P-935). b The graph illustrates LRRK2 phosphorylation normalized upon total LRRK2 (n = 6;
One-way Anova: *p < 0.05 Non Dys versus 6-OHDA °p < 0.01 Non dys versus Dysk, #p < 0.05, Dys versus 6-OHDA). Data are expressed as mean ±
SEM. c Rats were injected in the left striatum with LRRK2 IN-1 inhibitor or vehicle (control) and the total and phosphorylated LRRK2 levels were
evaluated by WB. d IN-1 reduced LRRK2 phosphorylation in vivo (n = 6; **p < 0.01, unpaired two-tailed Student’s t-test). Graph reports LRRK2
phosphorylation level normalized on the total amount of LRRK2 protein. Data are expressed as mean ± SEM
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Fig. 2 (See legend on next page.)
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session (Fig. 2e). Accordingly, western-blotting analysis
revealed a significant decrease of Ser-935 phosphoryl-
ation in animals sacrificed 54 h after inhibitor III injec-
tion (Fig. 2f-g).
Discussion
In the last decades, the understanding of the molecular
mechanisms underlying LIDs onset has greatly advanced
[1]. However, there is still a relevant discrepancy be-
tween such knowledge and the availability of therapeutic
strategies able to prevent or ameliorate LIDs. Here we
show that LRRK2 phosphorylation level is increased in
non dyskinetic rats and that pharmacological inhibition
of LRRK2 worsens the dyskinetic motor behaviour in
parkinsonian animals chronically treated with L-DOPA.
Besides its potential role at the presynaptic site [14–17],
LRRK2 has been implicated in the morphological and
functional maturation of dendritic spines. In particular, it
has been suggested that LRRK2 influences synaptogenesis
and D1R and GluR1 signalling via PKA [11]. Furthermore,
we have recently demonstrated that LRRK2 interacts with
and phosphorylates N-ethylmaleimide sensitive factor
(NSF) [17]. NSF is relevant not only for vesicle recycling
at the presynaptic bouton, but it is also crucial to allow
proper expression of α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) and D1R receptors at the
postsynaptic membrane [18]. In particular, PKC γ-induced
trafficking of AMPA receptors depends on NSF and
PICK1 [19]. Overall, it could be argued that LRRK2 might
influence the composition and the functionality of synap-
tic receptor repertoire expressed on striatal neurons.
LRRK2 activity is tightly regulated by a still unre-
solved balance between auto/heterophosphorylation.
Serine phosphorylation is required for binding to 14-3-3.
Dephosphorylation results in LRRK2:14-3-3 complex dis-
sociation [20, 21] with subsequent LRRK2 relocalization
into defined cellular compartments including cytoskeletal
elements and centrosomes [20, 22]. Several kinases, in-
cluding PKA and PKCz, phosphorylate LRRK2 at Ser-935
in vitro, thus potentially positioning LRRK2 within the sig-
nalling cascade triggered by D1R/D2R. Given the impact
of LRRK2 not only on PKA and NSF but also on ERK1/2
pathway, we believe that D1R/D2R activity influences re-
ceptor expression and output acting via LRRK2. Finally,
notwithstanding one previous study on levodopa-treated
Israeli PD patients reported no over effect of G2019S mu-
tation on LID prevalence or latency [23], it will be of great
relevance the investigation of LID development in LRRK2
transgenic models, including loss-of-function and knock-
in.
Conclusions
Our data suggest that the molecular alteration under-
lying LIDs could impinge on LRRK2 and that the estab-
lishment of treatments restoring/preserving proper
LRRK2 phosphorylation level would be of great thera-
peutic value for LIDs prevention.
Material and methods
Animals
Adult male Sprague Dawley rats (Charles River Labora-
tories, Calco, Italy) were maintained on a 12-h light/dark
cycle at 22 °C with food and water ad libitum. Proce-
dures were carried out in accordance with the current
European Law (Directive 2010/63/EU).
Antibodies
The primary antibodies used in this study are rabbit
anti-LRRK2 1:500 MJFF C41-2, rabbit anti-LRRK2 P-
Ser-935 UDD2 10(12) (Abcam, Cambridge, UK), mouse
anti-actin 1:1000, mouse anti-FLAG 1:1000, mouse anti
myc 1:1000, mouse anti-synaptophysin 1:1000 (Sigma-
Aldrich St. Louis, MO, USA).
(See figure on previous page.)
Fig. 2 Effects of LRRK2 inhibitors on dyskinesia in 6-OHDA parkinsonian rats. a The panel is a schematic representation of the experimental
design. Rats were unilaterally injected with 6-OHDA in the left MFB. After 15 days, the extent of the lesion was evaluated upon apomorphine
answer. Two months after the 6-OHDA injection, fully lesioned rats (>200 controlateral turns) were chronically treated with L-DOPA. LRRK2
inhibitors were administrated to low dyskinetic animals with a single intrastriatal (i.s.) injection after 2 weeks of L-DOPA treatment. LIDs onset and
severity were evaluated by AIMs scoring. b IN-1 (5 nmol), LRRK2 inhibitor III (5 nmol) or vehicle (5 μl 0.5 % DMSO) were stereotaxically injected in
the ipsilateral striatum of low dyskinetic rats. I.s. injections were performed 6 h before the daily L-DOPA administration and the evaluation of AIMs
were carried out from 20 to 140 min after L-DOPA. Both inhibitors were able to induce a significant increase in the AIMs score compared to
vehicle injected rats and to pre-surgery values (n = 7; −18 h: ***p < 0.001, DYS vs DMSO/IN-1/Inh. III. 6 h: ***p < 0.001, DYS vs DMSO/IN-1/Inh. III.
54 h: ***p < 0.001, DMSO vs IN-1/Inh. III/DYS. IN-1: ***p < 0.001, 54 h vs −18 h/6 h. Inhibitor III: ***p < 0.001, 54 h vs −18 h/6 h vs 54 h; two-way
ANOVA followed by Bonferroni post-hoc test). c-e Both inhibitors significantly increased dyskinesia induction, as indicated by AIMs scoring during
the single last observation session (54 h; E) (n = 7; 40 min, DMSO vs IN-1/Inh. III: *p < 0.05, DMSO vs DYS: **p < 0.01; 60 min, DMSO vs Inh. III: **p <
0.01, DMSO vs DYS: ***p < 0.001; 80 min, DMSO vs DYS: ***p < 0.001; 100 min, DMSO vs Inh. III: **p < 0.01, DMSO vs DYS: ***p < 0.001; 120 min,
DMSO vs Inh. III: **p < 0.01, DMSO vs DYS: ***p < 0.001; two-way ANOVA plus Bonferroni post-hoc test). f The ipsilateral striatum from rats
displaying a dyskinetic behaviour (Dys), non dyskinetic rats (Non Dys), Non Dys animals sacrificed 6 h after Inh-III injection (Inh-III 6 h) or Non Dys
animals sacrificed 54 h after Inh-III injection (Inh-III 54 h) were analyzed by WB to evaluate the levels of LRRK2 phosphorylation at Ser-935 site
(P-935). g The graph illustrates LRRK2 phosphorylation normalized upon total LRRK2 (n = 3; One-way Anova: *p < 0.01 Non Dys versus Dys
#p < 0.05 Non Dys versus Inh-III 54 h). Data are expressed as mean ± SEM
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6-hydroxydopamine (6-OHDA) rat model
Rats (n = 100; 125–175 g) underwent a single stereotaxic
injection of 6-OHDA (Sigma-Aldrich, St. Louis, MO,
USA; 12 μg/4 μl, rate of injection 0.38 μl/min) in the left
medial forebrain bundle (MFB; AP: +4.4, L: −1.2; DV:
−7.5) as previously described [24, 25]. Fifteen days after
the lesion, the rats were challenged with 0.05 mg/kg
apomorphine (Sigma-Aldrich; s.c. injection) to assess
the entity of the lesion. Rats with a complete DA de-
nervation (fully lesioned rats) were enrolled in the
study.
L-DOPA-induced dyskinesias (LIDs) and treatment with
LRRK2 inhibitors
Two months after the 6-OHDA injection, fully lesioned rats
were treated with 6 mg/kg L-DOPA and 6 mg/kg bensera-
zide (1 s.c. injection/day) for 14 days. L-DOPA-induced ab-
normal involuntary movements (AIMs) were evaluated on
days 4, 7, 10 and 14 of L-DOPA administration using a
highly validated rat AIMs scale [25, 26]. In brief, rats were
observed individually for 1 min every 20 min from 20 to
140 min after the daily L-DOPA injection. At each observa-
tion time point the AIMs were classified into 3 subtypes: i.
axial (dystonic or choreiform torsion of the upper part of
the body toward the side contralateral to the lesion), ii. limb
(jerky and/or dystonic movements of the forelimb contra-
lateral to the lesion) and iii. orolingual (empty jaw move-
ments and tongue protrusion). Each subtype was scored on
a severity scale from 0 to 4 (0 = absent, 1 = present during
less than half of the observation time (<30 s), 2 = present
for more than half of the observation time (>30 s),
3 = present for 1 min but suppressible by external
stimuli, 4 = present all the time but not suppressible
by external stimuli). The total AIMs score for each
test session was obtained by summing the scores of
all observation time points. Animals were then di-
vided in 2 groups according to their AIMs score:
rats with low (AIMs <15) and high (AIMs > 25) dys-
kinetic behaviour.
At day 15 of L-DOPA administration, fully lesioned
rats showing a low dyskinetic behaviour underwent a
single stereotaxic injection of 2 LRRK2 inhibitors IN-1
(5 nmol; n = 7) and Inhibitor III (5 nmol; n = 7), or 0.5 %
DMSO (n = 7) in the ispilateral striatum (AP = +0.2, L =
+3.5, DV = −5.7; rate of injection 0.5 μl/min). Untreated
fully lesioned animals displaying stable and severe dys-
kinesia (AIMs >25; n = 7) were included in the study as
positive control. L-DOPA treatment was continued for
4 days after injection of LRRK2 inhibitors. To evaluate
the effects of LRRK2 inhibition on dyskinesia, AIMs as-
sessment on IN-1/InhibIII/DMSO-treated rats was car-
ried out before the surgery (−18 h), on the day of the
surgery and after 2 days (6 and 54 h after the injection,
respectively).
Western blot (WB)
Striata from 6-OHDA and L-DOPA-treated non dyski-
netic and dyskinetic rats were dissected and solubilized
in 150 mM NaCl, 50 mM Tris pH 7.4, 1 % v/v NP-40,
0.1 % v/v SDS with protease and phosphatase inhibitors.
The contralateral striatum from 6-OHDA rats was used
as control. Proteins were separated by SDS-PAGE, trans-
ferred onto a nitrocellulose membrane and incubated
with the appropriate primary and secondary antibodies.
Labeling was visualised by ECL chemiluminescence de-
tection system and quantification was performed by
densitometric analysis of the fluorograms (Quantity One
software, Bio-Rad, Hercules, CA, USA).
Statistical analysis
All data are expressed as mean ± SEM. Significance of the
differences was analysed by unpaired two-tailed Student’s
t test or ANOVA followed by Dunn’s and Bonferroni post
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